Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Accumulated Expenses: 2012-2025

Historic Accumulated Expenses for Agios Pharmaceuticals (AGIO) over the last 13 years, with Sep 2025 value amounting to $37.2 million.

  • Agios Pharmaceuticals' Accumulated Expenses rose 11.74% to $37.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.2 million, marking a year-over-year increase of 11.74%. This contributed to the annual value of $46.9 million for FY2024, which is 8.56% up from last year.
  • Latest data reveals that Agios Pharmaceuticals reported Accumulated Expenses of $37.2 million as of Q3 2025, which was up 5.46% from $35.3 million recorded in Q2 2025.
  • In the past 5 years, Agios Pharmaceuticals' Accumulated Expenses ranged from a high of $46.9 million in Q4 2024 and a low of $19.7 million during Q1 2022.
  • Over the past 3 years, Agios Pharmaceuticals' median Accumulated Expenses value was $33.3 million (recorded in 2024), while the average stood at $32.8 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first plummeted by 41.21% in 2021, then soared by 42.23% in 2023.
  • Over the past 5 years, Agios Pharmaceuticals' Accumulated Expenses (Quarterly) stood at $32.0 million in 2021, then dropped by 5.06% to $30.4 million in 2022, then spiked by 42.23% to $43.2 million in 2023, then grew by 8.56% to $46.9 million in 2024, then rose by 11.74% to $37.2 million in 2025.
  • Its Accumulated Expenses stands at $37.2 million for Q3 2025, versus $35.3 million for Q2 2025 and $20.8 million for Q1 2025.